RARE News and Press, Ultragenyx Pharmaceutical Inc. From 10/14/23

Phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annualized fracture rate associated with continuous and meaningful improvements in bone mineral density (BMD) Ultragenyx hosting Analyst Day on Monday, October 16 at 8:30 a.m. ET NOVATO, Cal...

NOVATO, Calif., Oct. 09, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that data from its ongoing late-stage program evaluating setrusumab (UX143) in osteogenesis imperfecta (OI) will be presented at the American Society for Bone and Mineral Research 2023 ...

NOVATO, Calif., Oct. 05, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultrarare genetic diseases, will host an Analyst Day at 8:30 a.m. ET on Monday, October 16,...

TORONTO, Sept. 25, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultrarare genetic diseases, today announced the approval of Evkeeza ® (evinacumab) in Ca...

2023-09-24 23:33:31 ET Summary Kyowa Kirin shares are viewed as a cheap option on the positive outcome for the atopic dermatitis drug being developed with Amgen. The company's recent track record for new drug trial success has been poor, but the partnership with Amgen provides rea...

2023-09-21 18:10:58 ET Summary Mereo BioPharma's extended financial runway and reduced R&D spend improve its short-term risk profile. Diverse pipeline, led by setrusumab and alvelestat, offers long-term growth but awaiting key clinical readouts. The company's etigilimab co...

Citi BioPharma Conference on September 6 in Boston Morgan Stanley Healthcare Conference on September 12 in New York City NOVATO, Calif., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commer...

2023-08-30 16:15:16 ET Summary Ultragenyx Pharmaceutical Inc. shares have declined following Q2 numbers and a broader selloff in the healthcare sector. The company continues to show growth in product sales and progress in its clinical programs for setrusumab. Further catalysts...

VANCOUVER, British Columbia, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Tactical Resources Corp. (CSE: RARE) (OTC: USREF) (“ Tactical Resources ” or the “ Company ”) is pleased to announce that the Company has received confirmation from the TSX Venture Exchange (the &#x...

VANCOUVER, British Columbia, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Tactical Resources Corp. (CSE: RARE) (OTC: USREF) (“Tactical Resources” or the “Company”), a mineral exploration and development company focused on the rare earth elements that drive the critical technologi...